Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus - PubMed (original) (raw)
Comparative Study
. 2007 Apr 17;104(16):6758-63.
doi: 10.1073/pnas.0701266104. Epub 2007 Apr 5.
Chieko Kyogoku, Snaevar Sigurdsson, Irina A Vlasova, Leela R L Davies, Emily C Baechler, Robert M Plenge, Thearith Koeuth, Ward A Ortmann, Geoffrey Hom, Jason W Bauer, Clarence Gillett, Noel Burtt, Deborah S Cunninghame Graham, Robert Onofrio, Michelle Petri, Iva Gunnarsson, Elisabet Svenungsson, Lars Rönnblom, Gunnel Nordmark, Peter K Gregersen, Kathy Moser, Patrick M Gaffney, Lindsey A Criswell, Timothy J Vyse, Ann-Christine Syvänen, Paul R Bohjanen, Mark J Daly, Timothy W Behrens, David Altshuler
Affiliations
- PMID: 17412832
- PMCID: PMC1847749
- DOI: 10.1073/pnas.0701266104
Comparative Study
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus
Robert R Graham et al. Proc Natl Acad Sci U S A. 2007.
Abstract
Systematic genome-wide studies to map genomic regions associated with human diseases are becoming more practical. Increasingly, efforts will be focused on the identification of the specific functional variants responsible for the disease. The challenges of identifying causal variants include the need for complete ascertainment of genetic variants and the need to consider the possibility of multiple causal alleles. We recently reported that risk of systemic lupus erythematosus (SLE) is strongly associated with a common SNP in IFN regulatory factor 5 (IRF5), and that this variant altered spicing in a way that might provide a functional explanation for the reproducible association to SLE risk. Here, by resequencing and genotyping in patients with SLE, we find evidence for three functional alleles of IRF5: the previously described exon 1B splice site variant, a 30-bp in-frame insertion/deletion variant of exon 6 that alters a proline-, glutamic acid-, serine- and threonine-rich domain region, and a variant in a conserved polyA+ signal sequence that alters the length of the 3' UTR and stability of IRF5 mRNAs. Haplotypes of these three variants define at least three distinct levels of risk to SLE. Understanding how combinations of variants influence IRF5 function may offer etiological and therapeutic insights in SLE; more generally, IRF5 and SLE illustrates how multiple common variants of the same gene can together influence risk of common disease.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
Expression levels of IRF5 mRNA are influenced by a polymorphism in a proximal 3′ UTR polyA+ signal sequence. (a) Microarray data from 233 CEU cell lines carrying various genotypes for rs2004640 and rs10954213 were examined for expression levels of IRF5. (b) Schematic of the 3′ UTR region of IRF5. (c) Northern blot of 500 ng of polyA+ RNA from cell lines carrying the indicated genotypes at rs10954213 (three cell lines from unrelated individuals for each genotype) using a common proximal 3′ UTR probe. Blots were stripped and reprobed for GAPDH. (d) Quantitative _Taq_Man RT-PCR in EBV cell lines (n = 9) and in control peripheral blood mononuclear cells (n = 14) for levels of IRF5 isoforms carrying the short or long 3′ UTR. (e) Northern blot using β-globin and GFP cDNA probes in Tet-off 293 cells transfected with chimeric β-globin:IRF5 3′ UTR expression plasmids for either the A or G allele of rs10954213. GFP expression plasmids were cotransfected as a control. (f) Graph shows the decay of β-globin:3′ IRF5 UTR mRNAs after suppression of new transcription with doxycycline. Results represent four independent experiments. ∗, P < 0.05; ∗∗, P < 0.01. (g) Western blot for IRF5 in two cell lines for each of the indicated genotypes at rs10954213 by using monoclonal anti-IRF5 antibodies that recognize a C-terminal peptide sequence of IRF5. Blots were stripped and reprobed with antibodies to GAPDH. Representative of five independent experiments.
Fig. 2.
Three functional variants in IRF5 define risk and protective haplotypes for SLE. (a) Diagram showing the location of the three common functional alleles identified in IRF5. (b) Summary of IRF5 haplotypes and their association to SLE.
Similar articles
- Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus.
Kozyrev SV, Lewén S, Reddy PM, Pons-Estel B; Argentine Collaborative Group; Witte T; German Collaborative Group; Junker P, Laustrup H, Gutiérrez C, Suárez A, Francisca González-Escribano M, Martín J; Spanish Collaborative Group; Alarcón-Riquelme ME. Kozyrev SV, et al. Arthritis Rheum. 2007 Apr;56(4):1234-41. doi: 10.1002/art.22497. Arthritis Rheum. 2007. PMID: 17393452 - A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.
Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano MF; Argentine and Spanish Collaborative Groups; Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME. Graham RR, et al. Nat Genet. 2006 May;38(5):550-5. doi: 10.1038/ng1782. Epub 2006 Apr 16. Nat Genet. 2006. PMID: 16642019 - Exon 6 variants carried on systemic lupus erythematosus (SLE) risk haplotypes modulate IRF5 function.
Wen F, Ellingson SM, Kyogoku C, Peterson EJ, Gaffney PM. Wen F, et al. Autoimmunity. 2011 Mar;44(2):82-9. doi: 10.3109/08916934.2010.491842. Epub 2010 Aug 9. Autoimmunity. 2011. PMID: 20695768 Free PMC article. - IRF5-mediated signaling and implications for SLE.
Lazzari E, Jefferies CA. Lazzari E, et al. Clin Immunol. 2014 Aug;153(2):343-52. doi: 10.1016/j.clim.2014.06.001. Epub 2014 Jun 10. Clin Immunol. 2014. PMID: 24928322 Review. - The genetics and biology of Irf5-mediated signaling in lupus.
Kozyrev SV, Alarcon-Riquelme ME. Kozyrev SV, et al. Autoimmunity. 2007 Dec;40(8):591-601. doi: 10.1080/08916930701510905. Autoimmunity. 2007. PMID: 18075793 Review.
Cited by
- Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.
Lichtman EI, Helfgott SM, Kriegel MA. Lichtman EI, et al. Clin Immunol. 2012 Jun;143(3):210-21. doi: 10.1016/j.clim.2012.03.005. Epub 2012 Apr 6. Clin Immunol. 2012. PMID: 22525889 Free PMC article. Review. - Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing.
Connolly JJ, Hakonarson H. Connolly JJ, et al. J Biomed Biotechnol. 2012;2012:798924. doi: 10.1155/2012/798924. Epub 2012 May 10. J Biomed Biotechnol. 2012. PMID: 22654485 Free PMC article. Review. - Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus.
Cherian TS, Kariuki SN, Franek BS, Buyon JP, Clancy RM, Niewold TB. Cherian TS, et al. Arthritis Rheum. 2012 Oct;64(10):3383-7. doi: 10.1002/art.34571. Arthritis Rheum. 2012. PMID: 22674082 Free PMC article. - Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching.
Feng D, Yang L, Bi X, Stone RC, Patel P, Barnes BJ. Feng D, et al. Eur J Immunol. 2012 Jun;42(6):1477-87. doi: 10.1002/eji.201141642. Eur J Immunol. 2012. PMID: 22678902 Free PMC article. - The QTN program and the alleles that matter for evolution: all that's gold does not glitter.
Rockman MV. Rockman MV. Evolution. 2012 Jan;66(1):1-17. doi: 10.1111/j.1558-5646.2011.01486.x. Epub 2011 Nov 6. Evolution. 2012. PMID: 22220860 Free PMC article.
References
- Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. Nat Genet. 2006;38:1173–1177. - PubMed
- Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, Seddon JM. Nat Genet. 2006;38:1055–1059. - PubMed
- Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, et al. Nat Genet. 2006;38:550–555. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01 RR000079/RR/NCRR NIH HHS/United States
- 5 M01 RR-00079/RR/NCRR NIH HHS/United States
- AR 43727/AR/NIAMS NIH HHS/United States
- R56 AI057484/AI/NIAID NIH HHS/United States
- K02 AI052170/AI/NIAID NIH HHS/United States
- R01 AI049494/AI/NIAID NIH HHS/United States
- M01-RR-00052/RR/NCRR NIH HHS/United States
- M01 RR000052/RR/NCRR NIH HHS/United States
- R01 AR043727/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials